Ireland - English - HPRA (Health Products Regulatory Authority)

he clissmann - meglumine amidotrizoate sodium amidotrizoate - 20 millilitre

Ireland - English - HPRA (Health Products Regulatory Authority)

he clissmann - meglumine amidotrizoate sodium amidotrizoate - 20 millilitre

Ireland - English - HPRA (Health Products Regulatory Authority)

he clissmann - meglumine amidotrizoate sodium amidotrizoate - 40 millilitre

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

neove pharma australia pty limited - flunixin meglumine - unknown - flunixin meglumine benzene active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

mavlab pty. ltd. - flunixin meglumine - unknown - flunixin meglumine benzene active 0.0 - active constituent

Canada - English - Health Canada

jubilant draximage inc. dba jubilant radiopharma - gadopentetate dimeglumine - solution - 469mg - gadopentetate dimeglumine 469mg - other diagnostic agents

United States - English - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - gadopentetate dimeglumine (unii: rh248g8v27) (gadopentetate - unii:v7ok6j19hq) - gadopentetate dimeglumine 469.01 mg in 1 ml - magnevist injection is indicated for use with magnetic resonance imaging (mri) in adults, and pediatric patients (2 years of age and older) to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues. magnevist injection has been shown to facilitate visualization of intracranial lesions including but not limited to tumors. magnevist injection is indicated for use with mri in adults and pediatric patients (2 years of age and older) to facilitate the visualization of lesions with abnormal vascularity in the head and neck. magnevist injection is indicated for use in mri in adults and pediatric patients (2 years of age and older) to facilitate the visualization of lesions with abnormal vascularity in the body. magnevist is contraindicated in patients with: risk summary gbcas cross the placenta and result in fetal exposure and gadolinium retention. the human data on the association between gbcas and adverse fetal outcomes are limited and inconclusive (see data

United States - English - NLM (National Library of Medicine)

henry schein animal health - flunixin meglumine (unii: 8y3jk0jw3u) (flunixin - unii:356ib1o400) - flunixin meglumine 50 mg in 1 ml - indications horse: flunixiject™ injectable solution is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse. it is also recommended for the alleviation of visceral pain associated with colic in the horse. cattle: flunixiject™ injectable solution is indicated for the control of pyrexia associated with bovine respiratory disease, endotoxemia and acute bovine mastitis. flunixiject™ injectable solution is also indicated for the control of inflammation in endotoxemia. contraindications horse: there are no known contraindications to this drug when used as directed. intra-arterial injection should be avoided. horses inadvertently injected intra-arterially can show adverse reactions. signs can be ataxia, incoordination, hyperventilation, hysteria, and muscle weakness. signs are transient and disappear without antidotal medication within a few minutes. do not use in horses showing hypersensitivity to flunixin meglumine. cattle: nsaids inhibit production of

United States - English - NLM (National Library of Medicine)

norbrook laboratories limited - flunixin meglumine (unii: 8y3jk0jw3u) (flunixin - unii:356ib1o400) - flunixin 50 mg in 1 ml - there are no known contraindications to this drug in swine when used as directed. do not use in animals showing hypersensitivity to flunixin meglumine. use judiciously when renal impairment or gastric ulceration is suspected.

United States - English - NLM (National Library of Medicine)

bimeda, inc. - flunixin meglumine (unii: 8y3jk0jw3u) (flunixin - unii:356ib1o400) - flunixin meglumine 50 mg in 1 ml - indications horse :  flunazine® injectable solution is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse.  it is also recommended for the alleviation of visceral pain associated with colic in the horse. cattle :  flunazine® injectable solution is indicated for the control of pyrexia associated with bovine respiratory disease, endotoxemia and acute bovine mastitis.  flunazine® injectable solution is also indicated for the control of inflammation in endotoxemia. contraindications horse :  there are no known contraindications to this drug when used as directed.  intra-arterial injection should be avoided.  horses inadvertently injected intra-arterially can show adverse reactions.  signs can be ataxia, incoordination, hyperventilation, hysteria, and muscle weakness.  signs are transient and disappear without antidotal medication within a few minutes.  do not use in horses showing hypersensitivity to flunixin meglumine. cattle :  nsaids inhibit production of prostaglandins which are important in signaling the initiation of parturition. the use of flunixin can delay parturition and prolong labor which may increase the risk of stillbirth. do not use flunazine® injectable solution within 48 hours of expected parturition.  do not use in animals showing hypersensitivity to flunixin meglumine.  use judiciously when renal impairment or gastric ulceration are suspected.